The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited has issued over 7 million new shares at $0.14 each, under a Tranche 1 Placement, without disclosure to investors as per the Corporations Act. The company is in preliminary talks with RMW Cho Group Limited to potentially expand its rights to Photosoft™ technology into new territories or indications, although no binding agreement has been reached yet.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft™ technology for cancer treatment. The company holds licensing rights in Australia and New Zealand and is listed on the ASX. Research and clinical trials are supported by RMW Cho Group Limited, the licensor of the technology.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.65M
See more data about IVX stock on TipRanks’ Stock Analysis page.